5:08 PM
 | 
May 25, 2016
 |  BC Extra  |  Company News

Vitesse launches first newco Thunderbolt

Vitesse Biologics LLC (South San Francisco, Calif.) launched virtual newco Thunderbolt Pharma Inc. (South San Francisco, Calif.), which will house a preclinical dual antagonist program targeting BLyS (BAFF) and tumor necrosis factor (TNF) ligand superfamily member 13 ( TNFSF13; APRIL) to treat...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >